(Total Views: 616)
Posted On: 09/21/2020 11:41:12 AM
Post# of 155735
Re: ClosetInvestor #57159
ClosetInvestor,
I dont agree with you on the mTNBC. Enrollment has slowed because of COVID. The comment about strength of signal, and the lack of attention are simply because of slow enrollment.
The pace of enrollment in all indications have been slowed due to COVID, both because patients are avoiding the doctors office, but also because we are focusing our resources on COVID.
If we are successful in an approval for COVID, the income generated will also greatly improve the speed of trials. As will the name recognition of Leronlimab. IMO COVID CD12 represents a potential tipping point for this company, should we receive an EUA, or an approval.
I dont agree with you on the mTNBC. Enrollment has slowed because of COVID. The comment about strength of signal, and the lack of attention are simply because of slow enrollment.
The pace of enrollment in all indications have been slowed due to COVID, both because patients are avoiding the doctors office, but also because we are focusing our resources on COVID.
If we are successful in an approval for COVID, the income generated will also greatly improve the speed of trials. As will the name recognition of Leronlimab. IMO COVID CD12 represents a potential tipping point for this company, should we receive an EUA, or an approval.
(10)
(0)
